Exploring research on natural compounds, cellular detoxification, gut health protocols, and chronic illness recovery.
Investigations into natural compounds, cellular health mechanisms, and evidence-based wellness protocols.
Tapeworm slayer proves its repurposing chops with landmark COVID-19 RCT but are we asking the right questions about antiparasitic polypharmacy? No hype, just 2025 verified receipts.
Evidence-graded review of black seed oil (Nigella sativa) benefits, incorporating recent meta-analyses and systematic reviews. Separates clinical proof from traditional use and emerging research.
The fundamental questions that remain unanswered about DNA contamination, SV40 promoters, and long-term safety—questions that should have been resolved before mass deployment.
For over 100 years, evidence of spirochetal brain infection has been ignored. Now, the Spike Protein is using the same endothelial playbook. Here's the damning continuity.
Uncover the hidden history of Lyme disease and its connection to MS, what the microscopes show, why tests miss it, and how to lower the inflammatory load now.
Kevin McCairn PhD's research on amyloid fibrin microclots causing Long COVID and post-vaccination syndromes. Evidence for nattokinase treatment and the crisis of misdiagnosis.
Recent studies, including 2024-2025 work, indicate SARS-CoV-2 and its spike protein can persist for months, with links to immune changes, latent herpesvirus reactivation, and fibrin(ogen) amyloid microclots. These mechanisms may help explain features of Long COVID and some post-vaccination syndromes.
TL;DR The core finding: mRNA vaccines contain bacterial DNA with active SV40 promoter sequences—contamination confirmed by 9+ independent labs across four continents, with levels up to 627-fold above regulatory limits and 815-fold variance between batches....
The median 18-day gap from COVID symptom onset to death in nursing homes points to secondary bacterial pneumonia a treatable condition often overlooked as protocols tightened and empiric antibiotics were delayed.
When Pfizer switched from clinical trial production to mass manufacturing, they changed everything from DNA templates to purification methods. Internal emails reveal regulators were alarmed by unexpected DNA contaminants with known risks, while patent documents show manufacturers long understood these dangers.